2020
Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology
Yumeen S, Mirza FN, Lewis JM, Girardi M. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. Journal Of Investigative Dermatology 2020, 140: 2319-2325.e1. PMID: 33222758, DOI: 10.1016/j.jid.2020.09.020.Peer-Reviewed Original ResearchConceptsCombination regimensCutaneous malignanciesMalignant cellsRelevant mouse modelPotential synergistic combinationsAdvanced cutaneous malignanciesClinical trial designChou-Talalay methodCancer cell linesClinical outcomesTherapy regimensDefinitive cureTargeted therapyTumor cell heterogeneityDrug combinationsMouse modelTrial designPreclinical developmentDrug resistanceRegimensCombination indexSynergistic activityOff-target effectsCritical pathwaysCell lines
2016
Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction
Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal Of The American Academy Of Dermatology 2016, 74: 870-877. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCross-Sectional StudiesFemaleFlow CytometryHematologic TestsHumansInternationalityLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPolymerase Chain ReactionPractice Guidelines as TopicPredictive Value of TestsPrognosisRare DiseasesReceptors, Antigen, T-CellRetrospective StudiesSezary SyndromeSkin NeoplasmsSocieties, MedicalConceptsCutaneous T-cell lymphomaT-cell lymphomaCurrent clinical practiceClinical practicePredictive valueNegative predictive valuePositive predictive valueCurrent International SocietyT cell receptorImmunophenotypic abnormalitiesEvidence of clonalitySingle centerTumor burdenBlood assessmentClinical benefitPeripheral bloodCohort casesDisease burdenPolymerase chain reactionStaging criteriaChain restrictionRetrospective analysisMalignant cellsFlow cytometryDiagnostic algorithm
2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryTetrahydronaphthalenesConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2006
Transimmunization for cutaneous T cell lymphoma: A phase I study
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL patientsCell lymphomaMalignant cellsCD8 T cell poolPhase I clinical studyT cell poolSignificant mean reductionElectron beam therapyInfiltrative lesionsClinical studiesDendritic antigenBlood monocytesTransimmunizationMean reductionTumor loadingPatientsMonoclonal antibodiesMalignant leukocytesMinimal toxicityBeam therapyPhase ICell poolVivo contact